Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
13.744 / 17.026
#109945

Re: Farmas USA

ZIOP

--

FDA and NIH to loosen oversight of gene therapy development

Aug. 16, 2018 9:47 AM ET|By:  Douglas W. House, SA News Editor 

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing  trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study protocols, annual reports, amendments and serious adverse event reporting. Senior leaders in both organizations believe that there is no longer sufficient evidence to assert that the risks of gene therapy are entirely unique and unpredictable or that the field requires special oversight over and above the existing framework.

The changes, to be published in the Federal Register tomorrow, will further limit the role of NIH and the Recombinant DNA Advisory Committee (RAC), formed in 1974 to advise the NIH director on research related to the manipulation of nucleic acids, in assessing gene therapy protocols and the review of safety information. RAC review and reporting requirements to the NIH for human gene therapy protocols will be eliminated. The responsibilities of institutional BioSafety Committees (local research oversight) will also be revised making their human gene therapy protocols consistent with other research, subject to NIH Guidelines.

RAC will continue to advise the NIH on emerging biotechnologies.

https://seekingalpha.com/news/3383518-fda-nih-loosen-oversight-gene-therapy-development?app=1#email_link

#109946

Re: Farmas USA

ACAD
Hoy casi todo verde y ACAD para abajo sin freno. Me temo que puede irse a un solo digito en unos dias.

#109948

Re: Farmas USA

No tengo ni idea de AT. Pero anoche estuve echando un vistazo a gráficos de ésta y otras, y tiene un hueco pendiente de tapar, de 2013, en 8,5x creo recordar. Igual va hacia ahí. 

ACAD

#109949

Re: Farmas USA

ACAD
Esperemos que hasta ahi no. Seria un -37% sobre el precio de hoy. Seria 1 billon de capitalizacion pero con 200M de ventas anuales. Cash todavia, aunque lo quema rapido.
Seria demasiado castigo. Aunque aqui nunca se sabe que haran los que manejan el cotarro.

#109952

Re: Farmas USA

ACAD  con producto en el mercado --- ----- RSI/diario 34

MNLT con 4 productos en el mercado ---  RSI/diario 26

DVAX con importante vacuna en el mercado,---- RSI/diario 32

TSRO  oncofarmaco en el mercado ----RSI/diario 29

RDUS  con producto en el mercado ---  RSI/diario 26

-----------

Todas con RSI en sobreventa,y en los bajos de BBollinger o cerca de el,.. despues de sus ER 

Ana que buenos cortos nos hemos perdido aqui,eh!

Cual de ellas para medio largo plazo  mejor para entrar.?